Stocksigma LogoStocksigma Logo

Thyrocare Divests Nueclear Healthcare for Rs 141.4 Crore to Focus on Pathology

Thyrocare Technologies approved divesting its 100% stake in wholly owned subsidiary Nueclear Healthcare Limited (NHL) to Trovera Healthcare for ~Rs 141.40

Thyrocare Divests Nueclear Healthcare for Rs 141.4 Crore to Focus on Pathology

Thyrocare Technologies Ltd 路 Outcome 路 21 Sept 2026, 8:27 pm

Thyrocare Divests Nueclear Healthcare for Rs 141.4 Crore to Focus on Pathology Thyrocare Technologies approved divesting its 100% stake in wholly owned subsidiary Nueclear Healthcare Limited (NHL) to Trovera Healthcare for ~Rs 141.40 crore to exit radiology and focus on core pathology. The consideration comprises Rs 81.90 crore in cash and Rs 59.50 crore via 42,500 CCPS (~4.5% fully diluted stake) of Trovera. NHL contributed Rs 44.62 crore (5.38%) to consolidated turnover and Rs 83.55 crore (14.27%) to net worth in FY26. Additionally, Thyrocare will purchase NHL's Gurugram and Hyderabad lab properties for Rs 20.59 crore.

Original exchange filing (PDF)

More announcements from Thyrocare Technologies Ltd

All Thyrocare Technologies Ltd announcements